Overview

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Status:
Withdrawn

Trial end date:
2019-06-01

Target enrollment:

Participant gender:

Summary

A phase II, open label, single arm, single agent study using nivolumab in patients who failed 2 or more lines of previous chemotherapy for recurrent/metastatic NPC (At least 1 line should include platinum based chemotherapy)

Phase:

Phase 2

Details

Lead Sponsor:

The University of Hong Kong

Treatments:

Nivolumab